ReWalk Robotics Reports First Quarter 2016 Financial Results -Growth driven by U.S. Veterans Administration and Commercial Insurance Reimbursement- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA

Reports First Quarter 2016 Financial Results

-Growth driven by U.S. Veterans Administration and Commercial Insurance Reimbursement-

ILIT, ISRAEL / MARLBOROUGH, MA, May 5, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk"

or "the Company") today announced its financial results for

the three-month period ended March 31, 2016.

Highlights of and subsequent

to the first quarter include:

had a strong start to the year with a significant increase in revenues for the first quarter of 2016. Our efforts to build a solid

foundation for ReWalk in key areas including market development and reimbursement are delivering early and promising results.

Reimbursement remained a key focus area for us during the quarter. We secured our first comprehensive commercial payer policy,

and won our first coverage denial appeal enabling a ReWalker in the U.S. to receive a personal unit." stated Larry Jasinski,

Chief Executive Officer.

the initiation of the VA's prospective multi-year randomized trial resulted in their procurement of 20 ReWalk systems during

the quarter. We are proud to help the VA continue its ground-breaking work in developing clinical data to document the benefits

of walking again," stated Jasinski. "With the VA's national standard operating procedure that covers ReWalk

systems now fully implemented, we have now provided two ReWalk exoskeletons to veterans for home and community use. With these

early strategic successes, we will continue to build our foundation, prioritizing reimbursement efforts, demonstrating the benefits

of exoskeleton use through clinical studies and publications, building our sales pipeline and remaining at the forefront of product

innovation," concluded Jasinski.

Quarter 2016 Financial Results

was $2.1 million for the first quarter of 2016, compared with $635,000 in the first quarter of 2015, and up sequentially from

$1.3 million in the fourth quarter of 2015. 32 ReWalk systems were placed during the first quarter, compared with 13 ReWalk systems

placed in the prior year period, and 25 placed in the fourth quarter of 2015.

increased to 24% in the first quarter reflecting increased volumes and stronger ASPs.

expenses in the first quarter of 2016 were $6.9 million, compared with $5.6 million in the first quarter of 2015. Operating expenses

in the first quarter reflect investment in our commercial and reimbursement efforts.

was $(6.9) million for the first quarter of 2016 compared with a net loss of $(5.7) million in the prior year quarter. Non-GAAP

net loss for the first quarter was $(5.9) million compared with a non-GAAP net loss of $(5.1) million in the first quarter of

of net loss to non-GAAP net loss is included at the end of this press release.

31, 2016, ReWalk had $21.8 million in cash and cash equivalents. On January 4, 2016, ReWalk entered into a loan agreement with

Kreos Capital under which Kreos extended a line of credit for up to $20.0 million, of which ReWalk has currently drawn down $12.0

management will host its first quarter conference call as follows:

replay will be available shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International).

The passcode for the replay is 92679506.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with

spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through

the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel

and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

is a registered trademark of ReWalk Robotics Ltd. in Israel.

addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private

Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities

Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and,

in some cases, may be identified by words like "anticipate," "assume,"

"believe," "continue," "could,"

"estimate," "expect," "intend,"

"may," "plan," "potential,"

"predict," "project," "future,"

similar terms or phrases. The forward-looking statements contained in this press release are based on management's current

expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which

are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from

those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth,

including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk's ability

to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk's ability to achieve

reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical research program and clinical

results; ReWalk's ability to improve its products and develop new products; ReWalk's ability to maintain adequate

protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability

to repay its secured indebtedness; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to

maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under

the heading "Risk Factors" in ReWalk's Annual

Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission on February 29,

2016 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking

statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual

results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict

all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether

as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial

statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes

that the use of non-GAAP accounting measures, including non-GAAP net loss is helpful to its investors. These measures, which the

Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three months ended March

31, 2016 and 2015, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense

(ii) depreciation and (iii) non-cash financial expenses.

Because of varying available valuation

methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses,

the Company believes that providing non-GAAP financial measures that exclude share-based compensation expense, depreciation and

non-cash financial (income) expenses allow for more meaningful comparisons between operating results from period to period. Each

of the Company's non-GAAP financial measures is an important tool for financial and operational decision-making and for

evaluating our own operating results over different periods of time. The non-GAAP financial data are not measures of the Company's

financial performance under U.S. GAAP, and should not be considered as alternatives to operating loss or net loss or any other

performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly

comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate

non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations

in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be

different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on the

Company's reported financial results. Further, share-based compensation expense has been, and will continue to be for the

foreseeable future, a significant recurring expense in the Company's business and an important part of the compensation

provided to its employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as

a substitute for the directly comparable financial measures prepared in accordance with GAAP. ReWalk urges investors to review

the reconciliation of our non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely

on any single financial measures to evaluate the business.

Communications, Inc.

E: lwilson@insitecony.com

E: jwlach@mercuryllc.com

ReWalk Robotics Reports First Quarter 2016 Financial Results

ReWalk Robotics Ltd.

Condensed Consolidated Statements of Operations

In thousands except per share data